In an effort to get to the root of healthcare spending in the United States, the National Pharmaceutical Council launched the Going Below the Surface initiative.
In an effort to get to the root of healthcare spending in the United States, the National Pharmaceutical Council launched the Going Below the Surface initiative. In addition to examining the drivers of healthcare spending, the initiative is creating a national multistakeholder dialogue to determine best practices for optimizing spending.
Today, we speak with Bobby Dubois, MD, PhD, chief science officer and executive vice president, National Pharmaceutical Council, about the initiative, its goals, and what it has found so far.
To listen to the podcast, please login.
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Listen above or or through one of these podcast services:
Learn more about drug prices in the United States and efforts to lower them:
From Patient Advocates to Pharma, Groups Weigh in on Trump Blueprint for Drug Costs
Healthcare Spending Driven by Price, Not Utilization: JAMA Study
Mitigating Barriers to Cell and Gene Therapy Access
February 14th 2025Cell and gene therapies can be life-changing for patients with certain conditions, but the process of receiving them poses barriers for patients and caregivers that require multistakeholder solutions, according to a white paper from the National Pharmaceutical Council.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Dr John M. O'Brien Highlights Critical Role of Rebates in Employer Benefit Choices
August 5th 2024John M. O'Brien, PharmD, MPH, of the National Pharmaceutical Council, discusses his recent study, which sheds light on how important rebates are when choosing benefits for employers and who advises employers on these choices.
Read More